Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GILD

Gilead Sciences, Inc

Oct 30 • 04:00PM ET

118.44

-0.06 -0.05 %

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: ABBV BMY MRK PFE AMGN JNJ LLY VRTX REGN BIIB

| Held by: VTI VOO QQQ IVV SPY VTV XLV VYM QQQM IBB

Scroll to Statements

Index	NDX, S&P 500	P/E	23.56	EPS (ttm)	5.03	Insider Own	0.20%	Shs Outstand	1.24B	Perf Week	-1.90%
Market Cap	146.96B	Forward P/E	13.71	EPS next Y	8.64	Insider Trans	-5.63%	Shs Float	1.24B	Perf Month	6.56%
Enterprise Value	165.30B	PEG	0.89	EPS next Q	2.00	Inst Own	88.41%	Short Float	1.28%	Perf Quarter	4.65%
Income	6.31B	P/S	5.10	EPS this Y	75.26%	Inst Trans	1.03%	Short Ratio	2.28	Perf Half Y	14.71%
Sales	28.80B	P/B	7.48	EPS next Y	6.68%	ROA	11.55%	Short Interest	15.80M	Perf YTD	28.22%
Book/sh	15.84	P/C	22.53	EPS next 5Y	26.59%	ROE	33.26%	52W High	124.61 -4.95%	Perf Year	33.44%
Cash/sh	5.26	P/FCF	15.69	EPS past 3/5Y	-57.36% -38.13%	ROIC	15.09%	52W Low	86.08 37.59%	Perf 3Y	70.17%
Dividend Est.	3.15 (2.66%)	EV/EBITDA	12.03	Sales past 3/5Y	1.62% 5.17%	Gross Margin	78.49%	Volatility	2.08% 2.58%	Perf 5Y	94.83%
Dividend TTM	3.14 (2.65%)	EV/Sales	5.74	EPS Y/Y TTM	501.26%	Oper. Margin	38.09%	ATR (14)	2.86	Perf 10Y	10.07%
Dividend Ex-Date	Dec 15, 2025	Quick Ratio	1.15	Sales Y/Y TTM	3.69%	Profit Margin	21.91%	RSI (14)	51.62	Recom	1.73
Dividend Gr. 3/5Y	2.74% 4.10%	Current Ratio	1.32	EPS Q/Q	21.05%	SMA20	-0.32%	Beta	0.33	Target Price	129.86
Payout	805.23%	Debt/Eq	1.27	Sales Q/Q	1.64%	SMA50	2.44%	Rel Volume	1.18	Prev Close	118.50
Employees	17600	LT Debt/Eq	1.13	Earnings	Oct 30 AMC	SMA200	7.98%	Avg Volume	6.94M	Price	118.44
IPO	Jan 22, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.73% 4.31%	Trades		Volume	8,349,594	Change	-0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-25	Upgrade	Daiwa Securities	Neutral → Outperform	$128
Aug-08-25	Upgrade	Truist	Hold → Buy	$127
Jul-25-25	Upgrade	Needham	Hold → Buy	$133
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$125
Mar-04-25	Reiterated	Oppenheimer	Outperform	$115 → $132
Feb-18-25	Upgrade	Deutsche Bank	Hold → Buy	$120
Feb-13-25	Upgrade	DZ Bank	Hold → Buy	$108
Jan-10-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$87 → $113
Dec-10-24	Resumed	BofA Securities	Buy	$109
Nov-15-24	Initiated	Wolfe Research	Outperform	$110
Nov-14-24	Initiated	Citigroup	Buy	$125
Nov-08-24	Downgrade	Maxim Group	Buy → Hold
Oct-21-24	Upgrade	Leerink Partners	Market Perform → Outperform	$74 → $96
Oct-17-24	Initiated	Bernstein	Outperform	$105
Oct-07-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$78 → $100
Jul-08-24	Upgrade	Raymond James	Mkt Perform → Outperform	$93
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75

Show Previous Ratings

Oct-30-25 11:00PM	Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ... (GuruFocus.com)
06:30PM	Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:43PM	Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations (Investor's Business Daily)
05:15PM	Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates (Zacks)
04:45PM	Gilead Earnings Beat Expectations. The Stock Is Still Falling. (Barrons.com)
04:28PM	Loading…
04:28PM	Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations (StockStory)
04:11PM	Gilead: Q3 Earnings Snapshot (Associated Press Finance)
04:07PM	Covid Continues To Haunt Gilead. How One Drug Dinged Product Sales. (Investor's Business Daily)
04:06PM	Gilead Earnings Beat Expectations (Barrons.com)
04:02PM	Gilead Sciences Announces Third Quarter 2025 Financial Results (Business Wire)
11:19AM	Stock Market Today: Traders Look to Apple, Amazon Earnings To Redeem Megacap Tech (TheStreet)
Oct-29-25 08:58AM	Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings? (Zacks)
Oct-28-25 11:13PM	Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
10:00AM	Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline (Zacks)
Oct-27-25 11:05AM	What's in Store for These 5 Pharma Bigwigs This Earnings Season? (Zacks)
09:15AM	Loading…
09:15AM	Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Oct-23-25 10:00AM	Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-25 06:00PM	Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
08:57AM	What to Expect From Gilead Sciences' Next Quarterly Earnings Report (Barchart)
Oct-19-25 08:30AM	Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025 (Business Wire)
02:30AM	Trodelvy Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study (Business Wire)
Oct-17-25 09:43AM	Stock Market Today: Dow Up Amid Bank Fears; Eli Lilly, Novo Sell Off On Trump Comments (Live Coverage) (Investor's Business Daily)
Oct-16-25 03:51PM	RBC Warns Gilead (GILD) Faces Risk from Trump's Price Cut Target (Insider Monkey)
09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Oct-15-25 03:30AM	Gilead Presents New HIV Research Data at EACS 2025 - Driving Scientific Innovation in Treatment and Prevention (Business Wire)
Oct-14-25 07:51AM	Gilead and Arcus reignite anti-TIGIT interest with Phase II gastric cancer win (Clinical Trials Arena)
Oct-13-25 08:50AM	Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? (Zacks)
08:30AM	Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025 (Business Wire)
Oct-10-25 09:08PM	3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR (Zacks)
12:14PM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
04:05PM	Loading…
Oct-09-25 04:05PM	Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025 (Business Wire)
Oct-08-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-07-25 09:37AM	Gilead Resolves Patent Litigations for HIV Treatment Biktarvy (Zacks)
Oct-06-25 10:04AM	Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump (Investor's Business Daily)
09:19AM	Gilead stock rises after settling Biktarvy patent disputes (Investing.com)
06:07AM	Gilead delays arrival of Biktarvy copycats; CDC updates vaccine schedule (BioPharma Dive)
Oct-04-25 09:37AM	2 Surefire Dividend Stocks to Buy for the Long Haul (Motley Fool)
Oct-03-25 06:00PM	Gilead Sciences (GILD) Laps the Stock Market: Here's Why (Zacks)
06:28AM	RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD) (Insider Monkey)
05:33AM	Gilead Foundation Commits Over $6.5M in New Grant Funding to Support STEM Education Pathways (Insider Monkey)
Oct-02-25 09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:00AM	Gilead's Lost Decade Is Over. It's Time to Buy the Stock. (Barrons.com)
Oct-01-25 03:19PM	Trump Triggered a Rally in Drug Stocks. Why It Might Not Last. (Barrons.com)
09:38AM	Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline (Zacks)
Sep-30-25 02:49PM	What Do Analysts Think About Gilead Sciences (GILD)? (Insider Monkey)
Sep-29-25 01:39AM	Morgan Stanley Maintains Buy on Gilead Sciences (GILD) (Insider Monkey)
Sep-27-25 12:59AM	Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum (Insider Monkey)
Sep-26-25 10:48AM	JPMorgan Lifts Gilead Sciences, Inc. (GILD)'s Price Target To $145, Maintains Overweight Rating (Insider Monkey)
Sep-25-25 06:00PM	Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors (Zacks)
11:40AM	Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category (Insider Monkey)
08:00AM	Gilead Foundation Grants $6.5 Million in Commitment to STEM Education (Business Wire)
Sep-24-25 10:16AM	Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? (Zacks)
Sep-21-25 09:19AM	Gilead Sciences, Inc. (GILD) Expands U.S. Manufacturing Capacity With $32B Investment Through 2030 (Insider Monkey)
Sep-18-25 05:50PM	Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know (Zacks)
09:00AM	Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
Sep-17-25 06:00PM	Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note (Zacks)
Sep-16-25 02:58PM	Redburn Atlantic Maintains a Buy on Gilead Sciences (GILD), Sets a $143 PT (Insider Monkey)
12:02AM	3 Reasons GILD is Risky and 1 Stock to Buy Instead (StockStory)
Sep-15-25 11:53AM	Why Californias biopharma boom is critical for logistics (FreightWaves)
09:43AM	Biotech Sector May Flip to Market Leader by Year-End (MarketBeat)
Sep-14-25 05:30AM	Biotech stocks: Who wins and who loses if RFK, Jr. goes (Investing.com)
Sep-12-25 10:01PM	Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock (Benzinga)
Sep-11-25 05:50PM	Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider (Zacks)
03:25PM	Biotechs Could Benefit If RFK Jr. Leaves HHS (GuruFocus.com)
Sep-07-25 10:23AM	Leerink Partners Maintains Buy on Gilead Sciences (GILD) (Insider Monkey)
Sep-06-25 01:13AM	Gilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy (Insider Monkey)
Sep-05-25 05:00AM	Gilead Sciences advances HIV prevention with new US partnership (Pharmaceutical Technology)
Sep-04-25 04:21PM	The US will buy 2 million doses of an HIV prevention drug for low-income countries (Associated Press Finance)
02:15PM	Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries (Business Wire)
08:30AM	Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV (Business Wire)
02:57AM	Is Gilead Sciences Stock Underperforming the Nasdaq? (Barchart)
Sep-03-25 12:15PM	Gilead starts building manufacturing hub under $32 billion planned US investments (Reuters)
11:30AM	Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy (Business Wire)
12:36AM	1 Healthcare Stock to Consider Right Now and 2 We Question (StockStory)
Sep-02-25 11:13AM	What Do Analysts Think About Gilead Sciences (GILD)? (Insider Monkey)
03:28AM	Gilead Sciences, Inc. (GILD) Wins FDA Approval for World's First Twice-Yearly HIV Preventive Therapy (Insider Monkey)
Sep-01-25 04:00AM	Wyoming State Buys European Bank Stocks, Adjusts Healthcare Holdings (Barrons.com)
Aug-31-25 12:10AM	Gilead Sciences (GILD) Announces Marketing Authorization for Yeytuo from the European Commission (Insider Monkey)
Aug-28-25 09:00AM	Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock (Zacks)
Aug-27-25 02:56AM	Analyst Says Gilead (GILD) is a 'Very High Quality' Cheap Stock - Here's Why (Insider Monkey)
Aug-26-25 09:40AM	GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU (Zacks)
07:43AM	Gileads Yeytuo approved in EU, boosting its blockbuster potential (Pharmaceutical Technology)
04:57AM	Gilead wins European approval for HIV prevention injection (Investing.com)
03:02AM	Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win (Investor's Business Daily)
03:00AM	European Commission Authorizes Twice-Yearly Yeytuo (Lenacapavir) for HIV Prevention (Business Wire)
Aug-22-25 09:55AM	GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo (Zacks)
07:50AM	Suze Orman is known for money advice - now she's sharing her stock picks and biggest investing mistake (MarketWatch)
07:30AM	This Overlooked Biotech Stock Is a Buy for Its Hidden Strengths (Barchart)
06:53AM	Gileads Kite scoops in vivo CAR-T specialist Interius for $350m (Pharmaceutical Technology)
Aug-21-25 04:56PM	Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug (Investor's Business Daily)
12:15PM	Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn't Paying. (Barrons.com)
11:16AM	Why Gilead Sciences (GILD) Shares Are Sliding Today (StockStory)
11:12AM	Coty, Gilead Sciences, Rent the Runway: Trending tickers (Yahoo Finance Video)
09:50AM	Stock Market Today: Dow Jones Index Falls After Surprise Jobless Claims; Walmart Tumbles On Earnings Miss (Live Coverage) (Investor's Business Daily)
08:50AM	Gilead stock falls after CVS holds off adding HIV prevention shot to plans (Investing.com)
08:30AM	Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform (Business Wire)
Aug-20-25 04:41PM	Exclusive-CVS holds off adding Gileads new HIV prevention shot to drug coverage lists (Reuters)
04:05PM	Gilead Sciences to Present at Upcoming Investor Conferences (Business Wire)
Aug-18-25 09:25AM	GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait? (Zacks)
Aug-16-25 10:15AM	The Saturday Spread: These 3 Stocks Statistically May Be Cooking Up Something Special (GILD, WMB, XPEV) (Barchart)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Day Daniel Patrick	Chairman & CEO	Oct 28 '25	Sale	119.39	10,000	1,193,926	581,203	Oct 29 04:14 PM
DANIEL ODAY	Officer	Oct 28 '25	Proposed Sale	119.39	10,000	1,193,926		Oct 28 05:47 PM
Dickinson Andrew D	Chief Financial Officer	Oct 15 '25	Sale	118.08	2,500	295,200	157,055	Oct 16 09:35 PM
Mercier Johanna	Chief Commercial Officer	Oct 15 '25	Sale	118.08	3,000	354,240	110,193	Oct 16 09:28 PM
ANDREW DICKINSON	Officer	Oct 15 '25	Proposed Sale	118.08	2,500	295,200		Oct 15 04:05 PM
JOHANNA MERCIER	Officer	Oct 15 '25	Proposed Sale	118.08	3,000	354,240		Oct 15 04:03 PM
O'Day Daniel Patrick	Chairman & CEO	Sep 29 '25	Sale	111.66	10,000	1,116,564	591,203	Sep 30 04:57 PM
DANIEL O'DAY	Officer	Sep 29 '25	Proposed Sale	111.66	10,000	1,116,564		Sep 29 04:09 PM
Mercier Johanna	Chief Commercial Officer	Sep 15 '25	Sale	113.57	3,000	340,710	113,193	Sep 16 05:16 PM
Dickinson Andrew D	Chief Financial Officer	Sep 15 '25	Sale	113.57	2,500	283,925	159,555	Sep 16 05:12 PM
ANDREW DICKINSON	Officer	Sep 15 '25	Proposed Sale	113.57	2,500	283,925		Sep 15 04:38 PM
JOHANNA MERCIER	Officer	Sep 15 '25	Proposed Sale	113.57	3,000	340,710		Sep 15 04:04 PM
O'Day Daniel Patrick	Chairman & CEO	Aug 28 '25	Sale	113.63	10,000	1,136,300	595,725	Aug 29 04:16 PM
DANIEL O'DAY	Officer	Aug 28 '25	Proposed Sale	113.63	10,000	1,136,300		Aug 28 04:47 PM
Mercier Johanna	Chief Commercial Officer	Aug 15 '25	Option Exercise	66.64	25,000	1,666,000	128,968	Aug 18 08:56 PM
Mercier Johanna	Chief Commercial Officer	Aug 15 '25	Sale	118.53	28,000	3,318,927	114,168	Aug 18 08:56 PM
Dickinson Andrew D	Chief Financial Officer	Aug 15 '25	Sale	118.53	2,500	296,325	160,110	Aug 18 07:34 PM
ANDREW DICKINSON	Officer	Aug 15 '25	Proposed Sale	118.53	2,500	296,325		Aug 15 04:23 PM
JOHANNA MERCIER	Officer	Aug 15 '25	Proposed Sale	118.53	28,000	3,318,925		Aug 15 04:02 PM
O'Day Daniel Patrick	Chairman & CEO	Jul 28 '25	Sale	113.94	10,000	1,139,370	605,725	Jul 29 04:54 PM
DANIEL ODAY	Officer	Jul 28 '25	Proposed Sale	113.94	10,000	1,139,369		Jul 28 04:36 PM
Mercier Johanna	Chief Commercial Officer	Jul 15 '25	Sale	111.03	3,000	333,090	117,168	Jul 16 05:45 PM
Dickinson Andrew D	Chief Financial Officer	Jul 15 '25	Sale	111.03	2,500	277,575	162,610	Jul 16 05:41 PM
JOHANNA MERCIER	Officer	Jul 15 '25	Proposed Sale	111.03	3,000	333,090		Jul 15 04:36 PM
ANDREW DICKINSON	Officer	Jul 15 '25	Proposed Sale	111.03	2,500	277,575		Jul 15 04:03 PM
Bluestone Jeffrey	Director	Jul 14 '25	Option Exercise	67.45	5,000	337,250	13,920	Jul 15 03:59 PM
Bluestone Jeffrey	Director	Jul 14 '25	Sale	109.74	5,000	548,700	8,920	Jul 15 03:59 PM
JEFFREY BLUESTONE	Director	Jul 14 '25	Proposed Sale	109.74	5,000	548,700		Jul 14 04:01 PM
O'Day Daniel Patrick	Chairman & CEO	Jun 30 '25	Sale	110.45	10,000	1,104,484	615,725	Jul 01 06:02 PM
DANIEL O'DAY	Officer	Jun 30 '25	Proposed Sale	110.45	10,000	1,104,483		Jun 30 04:05 PM
Dickinson Andrew D	Chief Financial Officer	Jun 16 '25	Sale	110.17	2,500	275,425	165,110	Jun 17 06:08 PM
Mercier Johanna	Chief Commercial Officer	Jun 16 '25	Sale	110.17	3,000	330,510	120,168	Jun 17 06:04 PM
JOHANNA MERCIER	Officer	Jun 16 '25	Proposed Sale	110.17	3,000	330,510		Jun 16 04:05 PM
ANDREW DICKINSON	Officer	Jun 16 '25	Proposed Sale	110.17	2,500	275,425		Jun 16 04:01 PM
O'Day Daniel Patrick	Chairman & CEO	May 30 '25	Sale	110.42	10,000	1,104,193	620,268	Jun 02 08:55 PM
DANIEL O'DAY	Officer	May 30 '25	Proposed Sale	110.42	10,000	1,104,192		May 30 04:16 PM
Mercier Johanna	Chief Commercial Officer	May 22 '25	Option Exercise	66.64	25,000	1,666,000	136,652	May 23 03:16 PM
Mercier Johanna	Chief Commercial Officer	May 22 '25	Sale	107.52	28,000	3,010,564	121,152	May 23 03:16 PM
JOHANNA MERCIER	Officer	May 22 '25	Proposed Sale	107.52	28,000	3,010,562		May 22 04:01 PM
Dickinson Andrew D	Chief Financial Officer	May 15 '25	Sale	99.82	2,500	249,550	165,674	May 16 04:34 PM
ANDREW DICKINSON	Officer	May 15 '25	Proposed Sale	99.82	2,500	249,550		May 15 04:03 PM
Dickinson Andrew D	Chief Financial Officer	Apr 15 '25	Sale	106.40	2,500	266,000	168,174	Apr 16 03:22 PM
ANDREW DICKINSON	Officer	Apr 15 '25	Proposed Sale	106.40	2,500	266,000		Apr 15 04:04 PM
Dickinson Andrew D	Chief Financial Officer	Mar 17 '25	Sale	110.53	2,500	276,325	170,674	Mar 18 04:37 PM
ANDREW DICKINSON	Officer	Mar 17 '25	Proposed Sale	110.53	2,500	276,325		Mar 17 04:16 PM
Dickinson Andrew D	Chief Financial Officer	Mar 10 '25	Option Exercise	63.91	17,929	1,145,842	186,990	Mar 12 06:41 PM
Dickinson Andrew D	Chief Financial Officer	Mar 10 '25	Sale	118.17	17,929	2,118,696	169,061	Mar 12 06:41 PM
ANDREW DICKINSON	Officer	Mar 10 '25	Proposed Sale	118.17	17,929	2,118,695		Mar 10 04:02 PM
MERDAD V PARSEY	Officer	Mar 03 '25	Proposed Sale	115.70	21,910	2,534,913		Mar 03 04:26 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 18 '25	Buy	11.00	1,363,636	14,999,996	31,424,760	Feb 20 07:42 PM
Dickinson Andrew D	Chief Financial Officer	Feb 18 '25	Sale	104.09	2,500	260,225	169,061	Feb 19 04:43 PM
ANDREW DICKINSON	Officer	Feb 18 '25	Proposed Sale	104.09	2,500	260,225		Feb 18 04:14 PM
Dickinson Andrew D	Chief Financial Officer	Feb 12 '25	Option Exercise	67.27	137,676	9,260,873	308,899	Feb 13 09:13 PM
Dickinson Andrew D	Chief Financial Officer	Feb 12 '25	Sale	102.22	137,676	14,073,241	171,223	Feb 13 09:13 PM
ANDREW DICKINSON	Officer	Feb 12 '25	Proposed Sale	102.22	137,676	14,073,241		Feb 12 04:03 PM
Dickinson Andrew D	Chief Financial Officer	Jan 31 '25	Option Exercise	67.52	142,180	9,600,576	273,053	Feb 03 06:09 PM
Dickinson Andrew D	Chief Financial Officer	Jan 31 '25	Sale	97.22	142,180	13,822,740	129,873	Feb 03 06:09 PM
ANDREW DICKINSON	Officer	Jan 31 '25	Proposed Sale	97.22	142,180	13,822,740		Jan 31 04:15 PM
MERDAD V PARSEY	Officer	Jan 31 '25	Proposed Sale	98.00	184,683	18,098,989		Jan 31 04:01 PM
Dickinson Andrew D	Chief Financial Officer	Jan 15 '25	Sale	91.35	2,500	228,375	129,873	Jan 16 03:31 PM
ANDREW DICKINSON	Officer	Jan 15 '25	Proposed Sale	91.35	2,500	228,375		Jan 15 04:18 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 19 '24	Buy	21.37	940,499	20,098,464	2,209,471	Dec 23 08:26 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 18 '24	Buy	1.04	1,759,978	1,830,377	9,105,451	Dec 19 04:19 PM
Dickinson Andrew D	Chief Financial Officer	Dec 16 '24	Sale	91.96	8,500	781,660	132,373	Dec 17 05:27 PM
ANDREW DICKINSON	Officer	Dec 16 '24	Proposed Sale	91.96	8,500	781,660		Dec 16 04:08 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Option Exercise	70.50	248,645	17,528,577	387,564	Dec 03 02:43 PM
Dickinson Andrew D	Chief Financial Officer	Nov 29 '24	Sale	92.76	248,645	23,065,271	138,919	Dec 03 02:43 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Option Exercise	62.44	145,413	9,079,689	245,012	Nov 29 08:10 PM
Parsey Merdad	Chief Medical Officer	Nov 27 '24	Sale	91.92	164,211	15,094,013	80,801	Nov 29 08:10 PM
ANDREW DICKINSON	Officer	Nov 29 '24	Proposed Sale	92.76	248,645	23,065,258		Nov 29 02:35 PM
Bluestone Jeffrey	Director	Nov 26 '24	Option Exercise	61.24	10,000	612,442	15,708	Nov 27 06:14 PM
Bluestone Jeffrey	Director	Nov 26 '24	Sale	91.39	6,788	620,356	8,920	Nov 27 06:14 PM
MERDAD V PARSEY	Officer	Nov 27 '24	Proposed Sale	91.92	164,211	15,094,008		Nov 27 04:15 PM
Bluestone Jeffrey	Director	Nov 26 '24	Proposed Sale	91.39	6,788	620,356		Nov 26 07:31 PM
Mercier Johanna	Chief Commercial Officer	Nov 06 '24	Sale	91.28	5,000	456,400	73,127	Nov 07 04:38 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Option Exercise	57.92	25,000	1,448,000	125,189	Nov 07 04:32 PM
Parsey Merdad	Chief Medical Officer	Nov 06 '24	Sale	91.50	25,590	2,341,485	99,599	Nov 07 04:32 PM
MERDAD V PARSEY	Officer	Nov 06 '24	Proposed Sale	91.50	25,590	2,341,485		Nov 06 04:19 PM
JOHANNA MERCIER	Officer	Nov 06 '24	Proposed Sale	91.28	5,000	456,400		Nov 06 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GILD

Gilead Sciences, Inc

Upgrade your FINVIZ experience